This week, ZenPharm, the Maltese joint venture with Canadian cannabis producer, Zenabis Global, received its Maltese licence to process cannabis for medicinal use and research purposes out of its Hal Far Industrial Estate premises.
Kurt Farrugia, CEO of Malta Enterprise – the national economic development agency that assisted the company to set up locally – considers this “an important milestone for Malta’s medical cannabis industry.”
“We are gaining momentum with the production of cannabis for medical use in Malta,” he wrote. “Zenabis – a Maltese joint venture and partner of Zenpharm, have received a licence for the production of medical cannabis in their facility in Hal Far, Malta.”
The CEO said that the issuing of the second licence for the production of cannabis for medical use shows that “Malta is becoming a centre of excellence in such an important emerging sector.”
“Those companies strive hard to achieve the Medicine’s Authority pharmaceutical standards. Now that they do, patients can rest assured that the Made in Malta product is top quality. A gold standard for the industry. This is indeed a proud moment.”
Through its licence, ZenPharm plans to ship around 500kg of cannabis out of Malta annually to EU countries, with the largest market being Germany.
Featured Image:
Kurt Farrugia / LinkedIn
BOV announces new Chief Risk Officer and Chief People & Culture Officer
'We have taken these steps with our long-term strategy and stakeholders’ trust in mind,' BOV CEO says.
‘Private credit steps in when banks step back’: Apollo executive Jonathan Orr
He highlights how alternative lenders are increasingly filling financing gaps left by traditional banks, particularly during periods of market volatility.
Ras Al Khaimah is natural partner for db Group projects – Robert Debono
db Group’s family office SDH Capital opened a new office in Ras Al Khaimah.
‘AI doesn’t reduce bias, it scales it’ – Gege Gatt
The EBO.ai CEO said that the real opportunity in workplace artificial intelligence is not automation, but augmentation.
